title: MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population.
abstract: OBJECTIVE
  Mouse double minute 2 (MDM2) is a key negative regulator of the p53 activity. Recently, a polymorphism in the MDM2 intronic promoter, SNP309, was shown to influence MDM2 expression and p53 activity. We examined whether the SNP309 was related to the risk of developing nasopharyngeal carcinoma (NPC) among Chinese populations.
  
  
  METHODS
  We genotyped the SNP309 in two independent case-control populations in southern China, one is from Guangxi province (including 593 NPC patients and 480 controls) and the other is from Guangdong province (including 239 patients and 286 controls), by PCR direct sequencing. Multivariate logistic regression analysis was used to calculate adjusted odds ratio (OR) and 95% confidence interval (95% CI).
  
  
  RESULTS
  We observed that compared with the TT genotype, the genotypes containing G allele (GT + GG genotype) were associated with significant increased susceptibility to NPC in both Guangxi (OR, 1.43; 95% CI, 1.04-1.91) and Guangdong population (OR, 1.53; 95% CI, 1.00-2.36). When these two sample sets were combined, the OR of the GT + GG genotype developing NPC was 1.45 (95% CI, 1.12-1.85) compared with the TT genotype. Furthermore, compared with the TT genotype, the GT + GG genotype was also significantly associated with the advanced lymph node metastasis (OR, 1.84; 95% CI, 1.09-3.05).
  
  
  CONCLUSIONS
  Our findings suggest that the MDM2 SNP309 may be a risk factor for the occurrence and advanced neck lymph node metastasis of NPC in Chinese population.
authors.affiliation: Department of Genomics and Proteomics, Beijing Institute of Radiation Medicine, Beijing, China. zhougq@chgb.org.cn
authors.forename: Gangqiao
authors.initials: G
authors.lastname: Zhou
authors.forename: Yun
authors.initials: Y
authors.lastname: Zhai
authors.forename: Ying
authors.initials: Y
authors.lastname: Cui
authors.forename: Xiumei
authors.initials: X
authors.lastname: Zhang
authors.forename: Xiaojia
authors.initials: X
authors.lastname: Dong
authors.forename: Hao
authors.initials: H
authors.lastname: Yang
authors.forename: Ying
authors.initials: Y
authors.lastname: He
authors.forename: Kaitai
authors.initials: K
authors.lastname: Yao
authors.forename: Hongxing
authors.initials: H
authors.lastname: Zhang
authors.forename: Lianteng
authors.initials: L
authors.lastname: Zhi
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Yuan
authors.forename: Wei
authors.initials: W
authors.lastname: Qiu
authors.forename: Xiaoai
authors.initials: X
authors.lastname: Zhang
authors.forename: Yan
authors.initials: Y
authors.lastname: Shen
authors.forename: Boqing
authors.initials: B
authors.lastname: Qiang
authors.forename: Fuchu
authors.initials: F
authors.lastname: He
mesh_terms: D000328:Adult; D044466:Asian People / Q000235:genetics; D002681:China; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000235:genetics* / Q000473:pathology*; D009367:Neoplasm Staging; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic / Q000235:genetics; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics*; D012306:Risk
chemical_list: C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2